69results about How to "Reduce the risk of adverse reactions" patented technology

The invention discloses an omeprazole sodium freeze-dried powder injection and a preparation method thereof. The omeprazole sodium freeze-dried powder injection contains an active ingredient, namely, omeprazole sodium monohydrate, and auxiliary materials, namely, calcium disodium edetate and sodium hydroxide. The preparation method of the omeprazole sodium freeze-dried powder injection is characterized by comprising the following steps: weighing the calcium disodium edetate of prescription amount and dissolving the calcium disodium edetate in water for injection, stirring, dissolving, and regulating pH value to 10.0-12.0 by using 10% of sodium hydroxide solution; weighing omeprazole sodium of the prescription amount and adding the omeprazole sodium in the mixture, stirring at room temperature for dissolution, supplementing and adding the water for injection to full amount; adding active carbon, stirring at room temperature for decoloration and endotoxin removal, conducting rough filtration to remove carbon firstly, and then conducting refining filtration by using a filter membrane of 0.22 Mum; taking refining filtrate to test intermediate, conducting encapsulation after meeting requirements; and freeze-drying and unboxing, thus obtaining the omeprazole sodium freeze-dried powder injection. The freeze-drying technology of the omeprazole sodium freeze-dried powder injection takes temperature below minus 40 DEG C as pre-freezing temperature; after pre-freezing for at least two hours, sublimation is started, wherein the sublimation temperature is 5-12 DEG C, the sublimation time is over 14 hours; and then drying is conducted for over 2 hours at the temperature of 20-35 DEG C. Unboxing is carried out after a stopper is added and a cover is put in place, thus obtaining the finished product of the omeprazole sodium freeze-dried powder injection.

The invention discloses an egg yolk antibody for preventing novel goose astrovirus and a preparation method thereof. The egg yolk antibody contains a goose astrovirus strain resistance antibody; the preservation number of the goose astrovirus strain is CCTCC NO:V201808. The prepared egg yolk antibody is good in safety, and no any partial or whole adverse reaction is caused by the egg yolk antibody; infections caused by novel goose astrovirus can be effectively prevented and/or treated, and the good commercialization development prospect is achieved.

The invention provides a construction method of a kidney transplantation anti-infection drug dosage prediction model. The method comprises the following steps: establishing a group pharmacokinetic model of an anti-infective drug by adopting a nonlinear mixed effect model, a two-atrioventricular model and a mixed residual model through plasma concentration analysis, and calculating pharmacokinetic parameters of the corresponding model; and carrying out related hypothesis testing and estimation on the obtained model pharmacokinetic parameters based on a bootstrap method, visual prediction testing and normalized prediction distribution errors, and completing the steps of stability and prediction capability evaluation and the like. According to the established pharmacokinetic model of the kidney transplantation patient population, the reasonable judgment on the medication scheme information is accurately realized, the reference of the optimal dosage is expected to be provided in the infection prevention and treatment process, the adverse reaction risk is reduced, the curative effect is improved, and finally the individualized administration of the anti-infection medicine of the kidney transplantation patient is realized.

The invention discloses a method, device and system for guiding product improvement based on gray release. The method for guiding product improvement based on gray release comprises: releasing a gray product to a target user terminal which is screened according to predetermined pre-determined strategy; receiving feedback information sent by the target user terminal, wherein the feedback information comprises feedback information with multiple dimensions; analyzing and processing the feedback information in multiple dimensions, and performing merging and sorting according to a predetermined rule; and showing a directional chart and suggestion items guiding product improvement. A gray product is released to the target user terminal which is screened according to the predetermined pre-determined strategy for performing typical gray release. The feedback information in multiple dimensions is quickly obtained for guiding the product to improve and to be updated; a risk of bad reflection is reduced; and accurate detail information is obtained.

The invention discloses a stable ifenprodil tartrate injection which contains ifenprodil tartrate, an osmotic pressure regulator, a pH regulator and water for injection. The invention also discloses a preparation method of the stable injection. The stable ifenprodil tartrate injection is obtained by controlling the range of the pH value of the solution and insulating oxygen, thus avoiding use of an antioxidant and possible adverse reactions thereof. Sterility tests, accelerated tests and long duration tests prove the stable ifenprodil tartrate injection.

The invention belongs to the technical field of pharmaceutical chemistry and particularly relates to medical use of 7-hydroxy-butylphthalide in preparation of drugs for preventing and/or treating cardiac and cerebral vascular diseases.

The invention provides a stabilizing composition containing triethyl citrate and glycine. The composition is an aqueous solution, and the aqueous solution further comprises an active agent capable ofproducing ammonia by hydrolysis, wherein the weight ratio of the active agent to the triethyl citrate is from 1: 1 to 100: 1, and the weight ratio of the active agent to the glycine is from 1: 1 to 10: 1. The invention also relates to a method of stabilizing the aqueous solution containing the active agent capable of producing ammonia by hydrolysis, and relates to application of the stabilizing composition in a skin preparation for external use.

The invention provides a preparation method of a triple inactivated vaccine for pigs. The method determines an antigen composition with excellent immunization effects by selection of the antigen. The prepared polyvalent vaccine has outstanding immunization effects. The prepared vaccine contains a PCP immunization protective antigen exotoxin (Aps), has cross immunization protection effects better than those of a whole cell inactivated vaccine, greatly reduces side reaction, and can simultaneously prevent haemophilus parasuis, swine streptococcosis and actinobacillus pleuropneumonia by combined immunization with inactivated haemophilus parasuis and streptococcus suis. Compared with haemophilus parasuis and streptococcus suis inactivated vaccines sold on the market, the triple inactivated vaccine has the same corresponding pathogen immune protection force. Compared with the actinobacillus pleuropneumonia inactivated vaccine sold on the market, the triple inactivated vaccine has a cross immunization protecting force on diseased pigs with different serotypes and realizes multiple protection purposes.

The invention relates to a methylprednisolone sodium succinate freeze-dried powder injection. Every bottle of freeze-dried powder injection is prepared from 12-2550mg of methylprednisolone succinic acid, alkaline auxiliary material in which the sodium ion:succinic acid methylprednisolone mol ratio is 1:1, 0-200mg of excipient and pH value regulator. The powder injection is prepared by dissolving the components in the formula and carrying out freeze-drying. The invention is characterized in that the solvent is ethanol-containing water for injection, and the liquor prepared by dissolving the components in the formula in the solvent contains 5-10 vol% of ethanol.

The invention discloses a vector for recombinant expression of panda follicle-stimulating hormone, an expression system and a preparation method thereof, which relate to the technical field of gene engineering. The vector comprises a first gene for encoding a panda FSH alpha subunit and a second gene for encoding a panda FSH beta subunit, the sequence of the first gene is shown as SEQ ID NO.1, andthe sequence of the second gene is shown as SEQ ID NO.2. By constructing the vector and the expression system for recombinant expression of the panda follicle-stimulating hormone, stable and continuous active expression of the panda FSH alpha subunit, the FSH beta subunit and subunit compounds thereof can be realized. By using the panda-derived follicle-stimulating hormone, the risk of adverse reaction of organisms is reduced, and the breeding and propagation of varieties of rare endangered felines in China, such as giant pandas, small pandas and the like, are facilitated. In addition, the recombinant preparation method is simple and low in cost.

The invention discloses a Juno<TM>-based safety medication detection kit for children and a chip. The kit and the chip comprise primers at the following loci: HLA-DRB1*15:01-DQB1*06:02 loci of an HLAgene, an HLA-B*57:01 locus of the HLA gene, an HLA-B*15:02 locus of the HLA gene, an HLA-B*58:01 locus of the HLA gene, a rs267606617 locus of an MT-RNR1 gene,a rs267606618 locus of the MT-RNR1 gene,a rs267606619 locus of the MT-RNR1 gene, a rs1057910 locus of a CYP2C9 gene, a rs4244285 locus of a CYP2C19 gene, a rs4986893 locus of the CYP2C19 gene, a rs1065852 locus of a CYP2D6 gene, and a rs2242480 locus of a CYP3A4 gene.

The invention relates to a medicinal composition for treating diabetes, and its application in the preparation of medicines for treating the diabetes. The medicinal composition comprises glycine and metformin hydrochloride, and the best mass ratio of glycine to metformin hydrochloride is 3:1, 4:1 or 5:1. The cooperation of glycine and metformin hydrochloride realizes a reinforced effect or a synergistic effect, so the use effect of the medicinal composition can be improved. The administration concentrations of glycine and metformin hydrochloride are reduced on the premise that a same treatment effect is obtained, so the generation risk of adverse reactions is reduced.